1292841-28-1

1292841-28-1 structure

Name: Lapaquistat-d9 acetate
Chemical Name: Lapaquistat-d9 acetate
CAS Number: 1292841-28-1
Molecular Formula: C₃₃H₃₂D₉ClN₂O₉
Molecular Weight: 654.20
Catalog: Research Areas Metabolic Disease
Create Date: 2021-11-09 12:13:53
Modify Date: 2024-01-19 17:38:09
Lapaquistat-d9 acetate (TAK-475-d9) is the deuterium labeled Lapaquistat acetate. Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway[1]. Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research[2].

Name	Lapaquistat-d9 acetate

Description	Lapaquistat-d9 acetate (TAK-475-d9) is the deuterium labeled Lapaquistat acetate. Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway[1]. Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research[2].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Stein EA, et al. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation. 2011 May 10;123(18):1974-85. [3]. Marcuzzi A, et al. Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice. Curr Med Chem. 2018;25(24):2783-2796. [4]. M Shiomi, et al. Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions. Br J Pharmacol. 2008 Jul;154(5):949-57.

Molecular Formula	C₃₃H₃₂D₉ClN₂O₉
Molecular Weight	654.20

1292841-28-1	189060-13-7
1431291-46-1	1781417-68-2
1420043-63-5	358731-03-0
1173021-73-2	1219804-02-0
98006-44-1	2712126-48-0